Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441759 ((R)-3-(5-(3-Chlorophenyl)-2,3-dihydro-1H-pyrrolo[2...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441743 (3-Fluoro-3-(5-(2-fluoro-5- methylphenyl)indoline-1...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441755 (Trans-3-methyl-4-(5-phenyl-2,3-dihydro-1H-pyrrolo[...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441713 (US10640498, Example 10) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441715 ((S)-3-(5-(3-Chlorophenyl)indoline-1-carbonyl)pyrro...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441706 (US10640498, Example 3) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441711 (1-Cyano-3-fluoro-N-methyl-N-(5-phenylthiazol-2-yl)...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441725 (3-Fluoro-3-(5-phenyl-2,3-dihydro-1H-pyrrolo[2,3-b]...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441728 ((R)-3-(6-Phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazin...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441736 (1-Cyano-3-fluoro-N-methyl-N-(5-phenylisoxazol-3-yl...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441737 ((trans)-1-Cyano-4-(hydroxymethyl)-N-methyl-N-(5-ph...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441763 (US10640498, Example 60) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441716 ((trans)-3-(5-(2-Chlorophenyl)indoline-1-carbonyl)-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441717 (3-Fluoro-3-(5-phenylindoline-1-carbonyl)pyrrolidin...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441719 (3-Fluoro-3-(6-phenyl-2,3-dihydro-1-H-pyrrolo[2,3-b...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441726 ((S)-3-(6-Phenyl-1,2,3,4-tetrahydroquinoline-1-carb...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441753 ((R)-3-(4-(3-Ethylphenyl)indoline-1-carbonyl)pyrrol...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441742 (3-Fluoro-3-(5-(1-methyl-1H-indazol-5- yl)indoline-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441744 (3-Fluoro-3-(5-(5-methyl-1H-indazol-4- yl)indoline-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441750 (1-Cyano-N-methyl-N-((2-phenylthiazol-4-yl)methyl)p...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441752 (7-([1,1′-Biphenyl]-3-yl)-6-oxo-2,7-diazaspir...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441758 ((S)-3-(5-(3-Chlorophenyl)-2,3-dihydro-1H-pyrrolo[2...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441760 (3-Fluoro-3-(5-(pyridin-3-yl)indoline-1-carbonyl)py...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441768 (3-(5-(1-(3-Chlorobenzyl)-1H-pyrazol-5-yl)indoline-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441769 (3-(5-(1-(4-Chlorobenzyl)-1H-pyrazol-5-yl)indoline-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441721 ((S)-3-(5-Phenylindoline-1-carbonyl)pyrrolidine-1-c...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441722 (US10640498, Example 19) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441727 ((R)-3-(7-Phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazin...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441712 (N-(Benzo[d]thiazol-2-yl)-1-cyano-3-fluoro-N-methyl...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441718 (3-Fluoro-3-(6-phenylindoline-1-carbonyl)pyrrolidin...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441739 (3-Fluoro-3-(5-(1-methyl-1H-pyrazol-5- yl)indoline-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441745 (N-(3-(1-(1-Cyano-3-fluoropyrrolidine- 3-carbonyl)i...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441756 ((S)-3-Fluoro-3-(5-phenylindoline-1-carbonyl)pyrrol...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441757 ((R)-3-Fluoro-3-(5-phenylindoline-1-carbonyl)pyrrol...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441771 ((R)-1-(1-Cyanopyrrolidine-3-carbonyl)-4-(3-ethylph...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441746 (3-Fluoro-3-(5-(6-methoxypyridin-3- yl)indoline-1-c...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441730 ((S)-3-(4-Phenyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyrid...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441723 (US10640498, Example 20) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441732 ((S)-1-(1-Cyanopyrrolidine-3-carbonyl)-5-(1-methyl-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441764 ((R)-3-(5-(1H-Indazol-4-yl)-2,3-dihydro-1H-pyrrolo[...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441765 (3-Fluoro-3-(5-(1-(pyridin-2-ylmethyl)-1H-pyrazol-5...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441767 (3-(5-(1-(2-Chlorobenzyl)-1H-pyrazol-5-yl)indoline-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441731 ((S)-3-(4-(3-Chlorophenyl)-2,3-dihydro-1H-pyrrolo[2...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441734 ((S)-1-Cyano-N-methyl-N-(5-phenylpyridin-2-yl)pyrro...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441741 (3-Fluoro-3-(5-(4-(4-methylpiperazin-1- yl)phenyl)i...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441704 (US10640498, Example 1) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441707 ((S)-1-Cyano-N-methyl-N-(4-phenylpyridin-2-yl)pyrro...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441733 ((R)-3-(7-(1H-Pyrazol-1-yl)-3,4-dihydro-2H-benzo[b]...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441735 ((R)-1-Cyano-N-methyl-N-(5-phenylpyridazin-3-yl)pyr...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441738 (US10640498, Example 35) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441749 (1-Cyano-N-methyl-N-((3-phenylisoxazol-5-yl)methyl)...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441762 (3-(5-(1-Benzyl-1H-pyrazol-4-yl)indoline-1-carbonyl...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441766 (3-Fluoro-3-(5-(1-(pyridin-3-ylmethyl)-H-pyrazol-5-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441710 (1-Cyano-N-isopropyl-N-(4-phenylthiazol-2-yl)pyrrol...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441739 (3-Fluoro-3-(5-(1-methyl-1H-pyrazol-5- yl)indoline-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441761 (3-Fluoro-3-(5-(1-isobutyl-1H-pyrazol-5-yl)indoline...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441770 ( N-Benzyl-1-(1-cyano-3-fluoropyrrolidine-3-carbony...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441708 ((S)-1-Cyano-N-methyl-N-(6-phenylpyridin-2-yl)pyrro...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441724 ((S)-3-(5-Phenyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyrid...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441751 ((cis)-4-Oxo-5-(5-phenylthiazol-2-yl)hexahydropyrro...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441705 (1-Cyano-N-ethyl-N-(5-phenylthiazol-2-yl)pyrrolidin...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441729 ((R)-3-(8-Phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazin...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441748 (US10640498, Example 45) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441754 (3-(5-Phenyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441714 ((R)-3-(6-Phenylindoline-1-carbonyl)pyrrolidine-1-c...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441720 (US10640498, Example 17) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441747 ((R)-1-Cyano-N-(5-(4-cyanophenyl)pyridin-2-yl)-N-et...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441772 ((R)-1-(1-Cyanopyrrolidine-3-carbonyl)-N-methyl-4-p...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 5.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM441709 (1-Cyano-N-isopropyl-N-(5-(pyridin-4-yl)thiazol-2-y...) | PDB Reactome pathway UniProtKB/SwissProt UniProtKB/TrEMBL GoogleScholar | UniChem | US Patent | n/a | n/a | 6.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 M for a final concentration of 100 μM) in 50% DMSO in a 96-well polyprop... | US Patent US10640498 (2020) | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
